Health Products

Teva Canada Ranitidine Product Recall (2019-10-17)

· Published by Health Canada · Official notice

Details

Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type I

Summary

Product

A.  ACT-Ranitidine 150 mg Tablet;   

Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberBrand nameCompaniesDIN, NPN, DIN-HIMDosage formStrength
K50175, K50944, K51170, K51171, K51172, K51173B.  ACT-Ranitidine 300 mg Tablet
Recalling Firm
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
Marketing Authorization Holder
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
DIN 02248571TabletRanitidine 300 mg
K51136, K58444, K50205, K50860, K51114, K51139, K51141, K52964, K58446, K46486, K50593, K51071, K51076, K51144, K51146, K51148, K51150, K51152, K51154, K51164, K52965, K52966, K55591, K50203, K51069, K51132A.  ACT-Ranitidine 150 mg Tablet
Recalling Firm
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
Marketing Authorization Holder
Teva Canada Limited
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
DIN 02248570TabletRanitidine 150 mg

Introduction

A.  ACT-Ranitidine 150 mg Tablet;  

B.  ACT-Ranitidine 300 mg Tablet

Reason

Affected lots may be manufactured with an API containing an impurity, N-nitrosodimethylamine (NDMA).

Depth of distribution

Wholesalers, Healthcare Establishments, Retailers

For more information

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime